glp 1 agonist therapy GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Receptor Agonists as Treatments

A common thread among new treatments is the activation of energy- sensing pathways, especially AMP- activated protein kinase (AMPK), which helps the liver break down fatty acids, stops lipogenesis and reduces inflammation and fibrosis

doi: 10.1016/S2213-8587(19)30249-9 35 LeeJ

NNT, number needed to treat

8 Gastrointestinal side effects are most common, particularly during medication initiation and with dose escalation

& Butler, P

When the pharmacological appetite suppression is reduced or withdrawn, the caloric threshold required to maintain their new weight is lower than expected, but their appetite, shaped by the neurological reward pathways that GLP-1s modulate, does not stay suppressed indefinitely without ongoing treatment